189 related articles for article (PubMed ID: 32658035)
1. The Efficacy and Safety of Piribedil Relative to Pramipexole for the Treatment of Early Parkinson Disease: A Systematic Literature Review and Network Meta-Analysis.
Chen X; Ren C; Li J; Wang S; Dron L; Harari O; Whittington C
Clin Neuropharmacol; 2020; 43(4):100-106. PubMed ID: 32658035
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta-analysis.
Chen XT; Zhang Q; Wen SY; Chen FF; Zhou CQ
Eur J Neurol; 2023 Mar; 30(3):762-773. PubMed ID: 36380711
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis.
Li BD; Cui JJ; Song J; Qi C; Ma PF; Wang YR; Bai J
Cell Physiol Biochem; 2018; 45(1):119-130. PubMed ID: 29339630
[TBL] [Abstract][Full Text] [Related]
4. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis.
Chen XT; Zhang Q; Chen FF; Wen SY; Zhou CQ
Front Neurol; 2023; 14():1183823. PubMed ID: 37396766
[TBL] [Abstract][Full Text] [Related]
8. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
Zhao H; Ning Y; Cooper J; Refoios Camejo R; Ni X; Yi B; Parks D
Adv Ther; 2019 Jun; 36(6):1252-1265. PubMed ID: 30963514
[TBL] [Abstract][Full Text] [Related]
9. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M; Clarke J A
Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
11. Pramipexole for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M; Clarke J A
Cochrane Database Syst Rev; 2000; 2000(3):CD002261. PubMed ID: 10908540
[TBL] [Abstract][Full Text] [Related]
12. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
14. Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.
Zhang Q; Chen X; Chen F; Wen S; Zhou C
Eur J Pharmacol; 2023 Sep; 954():175884. PubMed ID: 37385577
[TBL] [Abstract][Full Text] [Related]
15. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
[TBL] [Abstract][Full Text] [Related]
16. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
Fedorova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):21-4. PubMed ID: 14681961
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Etminan M; Samii A; Takkouche B; Rochon PA
Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis.
Wang Y; Jiang DQ; Lu CS; Li MX; Jiang LL
Medicine (Baltimore); 2021 Nov; 100(44):e27511. PubMed ID: 34871213
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
Shen T; Ye R; Zhang B
Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
